Drug-rep union strikes back at pharma

The union for Italy's drug reps must have been studying military history: If you can't beat your opponent head-on, try a surprise attack from the side. Several big drug makers--including AstraZeneca, Pfizer, and Merck--have cut reps out of their sales networks by shifting staff to contract-employment companies. So the sales-rep union, Federisf, is asking the Italian government to slash prices paid to those drug makers for their products. After all, they're saving money on payroll, right?

The union also asked the government to withhold investment and research incentives from companies that have left significant numbers of reps out in the cold. The stakes are high for the reps at least: Federisf says one in three rep jobs could be lost, and a local daily newspaper estimated that 10,000 rep jobs are at risk in Italy.

- read the Pharmalot item
- here's the article from APM Europe

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.